Evaluation of Neoadjuvant Xaluritamig in Localized Prostate Cancer
a study on Prostate Cancer
Summary
- Eligibility
- for males ages 18 years and up (full criteria)
- Location
- at San Francisco, California and other locations
- Dates
- study startedstudy ends around
Description
Summary
The primary objectives of this study are to evaluate the safety and tolerability of xaluritamig administered in the neoadjuvant setting followed by radical prostatectomy and to evaluate the feasibility and safety of a radical prostatectomy following xaluritamig administered in the neoadjuvant setting.
Official Title
A Phase 1b, Open-Label, Multicenter Study Evaluating the Safety, Tolerability, and Feasibility of Neoadjuvant Xaluritamig Therapy Prior to Radical Prostatectomy in Subjects With Newly Diagnosed Localized Intermediate or High-Risk Prostate Cancer
Keywords
Prostate Cancer, Xaluritamig, AMG509, Localized Prostate Cancer, Neoadjuvant Therapy, Immunotherapy, T-Cell Engager, STEAP1, Prostatic Neoplasms
Eligibility
You can join if…
Open to males ages 18 years and up
Participants are eligible to be included in the study only if all the following criteria apply:
- Participants planned to undergo radical prostatectomy.
Histologically or cytologically confirmed adenocarcinoma of the prostate at initial biopsy, without neuroendocrine differentiation, signet cell, or small cell features.
Intermediate- or high-risk localized prostate cancer, defined as:
- Gleason score of 4+3 or higher AND initial PSA (iPSA) >10 OR
- Clinically advanced (cT3) on Magnetic Resonance Imaging (MRI) obtained within 3 months prior to screening AND/OR
- Positive locoregional lymph nodes as detected by prostate-specific membrane antigen-positron emission tomography (PSMA-PET) scans OR equal or ≤ 5 local lymph nodes on MRI can be enrolled.
- Participants must have undergone a PSMA-PET (CT or MRI) scan within 3 months prior to screening as part of the standard of care (SOC).
- Eastern Cooperative Oncology Group (ECOG) performance status of 0 to 1.
You CAN'T join if...
Participants are excluded from the study if any of the following criteria apply:
- Prior treatment for participant's prostate cancer.
- Any evidence of metastases outside of the surgical resection field identified by conventional imaging or PSMA-PET scans.
- Confirmed history or current autoimmune disease or other diseases resulting in permanent immunosuppression or requiring permanent immunosuppressive therapy.
- Participants with symptoms and/or clinical signs and/or radiographic signs that indicate an acute and/or uncontrolled active systemic infection within 7 days prior to the first dose of study treatment:
- Participant has known active infection requiring antibiotic treatment. Upon completion of antibiotics and resolution of symptoms, the participant may be considered eligible for the study from an infection standpoint.
- Recent history of arterial or venous thrombosis (eg, stroke, transient ischemic attack, pulmonary embolism, or deep vein thrombosis) within 6 and 3 months prior to the first dose of study treatment, respectively. Note: Participants with a history of venous thrombosis must be on stable anti-coagulation.
- Myocardial infarction and/or symptomatic congestive heart failure (New York Heart Association ≥ class II) within 12 months of first dose of xaluritamig with the exception of ischemia or non-ST segment elevation myocardial infarction controlled with stent placement more than 6 months prior to first dose of xaluritamig.
- Requirement for chronic systemic corticosteroid therapy unless stopped (with adequate tapering) within 7 days prior to dosing.
- Currently receiving treatment in another investigational device or drug study, or less than 4 weeks (since ending treatment on another investigational device or drug study[ies]). Other investigational procedures and participation in observational research studies while participating in this study are excluded with the exception of investigational scans.
Locations
- UCSF
accepting new patients
San Francisco California 94143 United States - Washington University
accepting new patients
Saint Louis Missouri 63110 United States
Details
- Status
- accepting new patients
- Start Date
- Completion Date
- (estimated)
- Sponsor
- Amgen
- Links
- AmgenTrials clinical trials website
- ID
- NCT06613100
- Phase
- Phase 1 Prostate Cancer Research Study
- Study Type
- Interventional
- Participants
- Expecting 40 study participants
- Last Updated
Frequently Asked Questions
Please contact me about this study
We will not share your information with anyone other than the team in charge of this study, which might include an external sponsor. Providing your contact details does not obligate you to participate in the research.
Thank you!
The study team should get back to you in a few business days.
You will also receive an email with next steps. Check your junk/spam folder if needed.
If you do not hear from the study team, please call 888-689-8273 and tell them you’re interested in study number NCT06613100.